The POC assay is being developed under a DoD contract to detect pathogens that may pose a threat to national security and public health.
The measures are part of a long-term plan for the National Health Service that will be rolled out across the country to detect 3 out of every 4 cancers at an early stage.
The handheld device uses CMOS technology for multiplexed measurement of disease-linked metabolites and could prove useful for inexpensive POC testing.
Its platform is being developed for several medical conditions using separate modules to measure cells, proteins, nucleic acids, enzymes, and small molecules.
The researchers have built a benchtop breath test currently being validated, but a commercial test could be more than a decade away.
Since introducing new clinical platforms last year, Sciex has launched an automated sample prep system while Thermo Fisher has begun customer beta testing.
LabCorp will be able to develop and commercialize the test for patients with an elevated PSA to determine their risk of having clinically significant prostate cancer.
A spin-out of the University of Geneva and Barcelona's Vall d’Hebron Research Institute, the company is focused on protein biomarkers for brain injury.
The researchers argued that fecal immunochemical test could be used as "rule-in" test for patients with ambiguous symptoms.
The researchers detected an average of 56 possible environmental organic acids present in each subject and confirmed the presence of six of them.